The use of DPP4 inhibitors alone further demonstrated positive trend of survival advantage in CRC patients, although it did reach significant statistic threshold with HR value of 0.87 and CI value of 0.75–1.00 (P = 0.055). The gene discussed is DPP4; the disease is colorectal carcinoma.